Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80

Benzinga Newsdesk www.benzinga.com Neutral 60.9%

Neg 0% Neu 60.9% Pos 0%

Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $89 to $80.